Since the reformation of the National Health Insurance Act in 2000, the Health Insurance Review and Assessment Service (HIRA) in the Republic of Korea has performed quality assessments for healthcare providers. The HIRA Value Incentive Program (VIP), established in July 2007, provides incentives for excellent-quality institutions and disincentives for poor-quality ones. The program is implemented based on data collected between July 2007 and December 2009. The goal of the VIP is to improve the overall quality of care and decrease the quality gaps among healthcare institutions. Thus far, the VIP has targeted acute myocardial infarction (AMI) and Caesarian section (C-section) care. The incentives and disincentives awarded to the hospitals by their composite quality scores of the AMI and C-section scores. The results of the VIP showed continuous and marked improvement in the composite quality scores of the AMI and C-section measures between 2007 and 2010. With the demonstrated success of the VIP project, the Ministry of Health and Welfare expanded the program in 2011 to include general hospitals. The HIRA VIP was deemed applicable to the Korean healthcare system, but before it can be expanded further, the program must overcome several major concerns, as follows: inclusion of resource use measures, rigorous evaluation of impact, application of the VIP to the changing payment system, and expansion of the VIP to primary care clinics.

Key words: Reimbursement, Incentives, Quality of health care, Quality improvement

J Prev Med Public Health 2012;45(3):148-155
FRAMEWORK OF THE VALUE INCENTIVE PROGRAM

I. History

The VIP, established in July 2007, provides incentives for excellent-quality institutions and disincentives for poor-quality ones [1,2]. The program was implemented based on data collected between July 2007 and December 2009. During this period, tertiary hospitals were evaluated for their rates of acute myocardial infarction (AMI) and Caesarean section (C-section). The results were announced based on these data, and the incentives were provided in the following year. Hence, a 1-year time lag exists between each period reflecting the clinical treatment performed and the reporting of the results.

The expanded VIP was launched in 2010. Data collection started in January 2010 and will continue until December 2012. Target institutions have been expanded to general hospitals, and target groups of incentives (and disincentives) have also been extended. The first results of the expanded VIP were announced in November 2011 and incentives were provided in December 2011.

II. Goal

The goal of the VIP is to improve the overall quality of care and decrease the quality gaps among healthcare institutions. Thus far, the VIP has targeted AMI and C-section care. The 30-day case fatality of AMI in Korea (6.3%) is the highest among the member countries of the Organization for Economic Cooperation and Development (OECD, average rate across OECD countries was 5.4% in 2009) [3]. The C-section rate in Korea (35.1%) is also among the highest levels of the OECD member countries (average rate across OECD countries was 25.8% in 2008) [3].

III. Target Hospitals

Forty-four tertiary hospitals have thus far been mandated to participate in the VIP for the following reasons. First, many of them already have mechanisms of quality assessment and experience with quality improvement. Second, they are expected to practice social accountability in terms of quality. Hospitals that are designated as tertiary hospitals are provided with an additional payment amounting to 30% of the total payment within the National Health Insurance.

IV. Quality Measures

To evaluate the quality of AMI care, the VIP has assessed six indicators to date: 1) the rate of thrombolytic drug administration within 60 minutes of hospital arrival; 2) the rate of primary percutaneous coronary intervention (PCI) performance within 120 minutes of arrival; 3) the rate of aspirin administration upon arrival (as a percentage of all arrival patients); 4) the rate of aspirin prescription at discharge (as a percentage of all discharge patients); 5) the rate of beta-blocker prescription at discharge (as a percentage of all discharge patients); and 6) the 30-day case fatality after hospitalization [4-10]. After measuring these six indicators, a composite quality score (CQS) is calculated for each hospital (Figure 1 shows the CQSs for VIP and expanded VIP). The rates of thrombolytic drug

| AMI composite quality score | Numerator | Denominator | Weight |
|-----------------------------|-----------|-------------|--------|
| Fibrinolytic therapy        | N1        | D1          |        |
| received within 60 min of   |           |             |        |
| arrival                     |           |             |        |
| Primary PCI received        | N2        | D2          |        |
| within 120 min of hospital  |           |             |        |
| arrival                     |           |             |        |
| Reperfusion group (A) =     | N1+N2     | D1+D2       | 4.5    |
| (N1+N2)/(D1+D2)             |           |             |        |
| Aspirin at arrival          | N3        | D3          |        |
| Aspirin prescribed at       | N4        | D4          |        |
| discharge                   |           |             |        |
| Beta-blocker prescribed at  | N5        | D5          |        |
| discharge                   |           |             |        |
| Medication group (B) =      | N3+N4+N5  | D3+D4+D5    | 2.5    |
| (N3+N4+N5)/(D3+D4+D5)       |           |             |        |

Outcome measure

Adjusted 30-day mortality rate: survival index (C) = [(A × 4.5) + (B × 2.5) + (C × 3.0)] / 100

Composite quality score = {[(A × 4.5) + (B × 2.5) + (C × 3.0)] / 100} × 100

C-section rate quality score

C-section rate quality score = (O - E) / SE

15 clinical risk factors

- Maternal factors: preeclampsia and eclampsia, bleeding, diabetes mellitus, age, venereal disease, gynecologic malignancy, placenta previa, placenta abruption, dystocia
- Neonatal factors: macrosomia, multiple gestation, cord prolapsed and vasa previa, fetal abnormality, malpresentation
- Other: previous C-section, premature birth

Figure 1. Calculation of Value Incentive Program’s composite quality score.

AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; C-section, Caesarian section.
administration and primary PCI performance were incorporated into the reperfusion indicators, and the rates of aspirin prescription at arrival and discharge and the rate of beta-blocker prescription were merged into the drug prescription rate. To produce the composite score, a relative weight was given to three indicators: 4.5 for reperfusion, 2.5 for drug prescription, and 3.0 for case fatality rate. In 2010, the thresholds of first and second measures of AMI were shortened from 60 minutes and 120 minutes to 30 minutes and 90 minutes.

The quality of the C-section rate was assessed by the quality score, which is the difference between the observed and expected C-section rates (Figure 1) [11-16]. The expected C-section rate was calculated by a multiple regression equation with 16 risk factors of C-section. Bleeding was excluded, and a total of 15 risk factors were used from 2010 (expanded VIP). Institutions are excluded when their total number of cases comes to less than 30, or when each indicator comprises fewer than 10 cases in AMI CQS.

The information needed for AMI quality assessment was gathered from the claims data warehouse and a Web-based hospital quality data acquisition system, while the C-section rate was calculated only with the claims data warehouse. Using an independent survey, the validity of the data was investigated. Institutions are excluded when their total number of cases comes to less than 30 in C-section CQS.

There are four steps from the development to utilization of the measures. The first step leads to developing a plan for the included items, institutions, periods, inclusion/exclusion criteria, and utilization of results. The next step is to formulate a detailed plan for each item, and when medical advice is required, it can be collected by an expert consultative body. The third step is to execute the assessment plan including data collection, analysis, etc. The last step is to disclose the assessment results and pay for performance (e.g., VIP). The central assessment committee, which was established by Article 59 of the National Health Insurance Act, reviews each step of the assessment implementation procedures.

V. Applying Incentives

The VIP was designed after the Premier Hospital Quality Incentive Demonstration Project of the United States Centers for Medicare and Medicaid Services (Figure 2). The hospitals were categorized into five performance grades by the composite quality scores of the AMI and C-section scores. In the first year, the performance grade of each hospital was reported to the public, but the incentive or penalty was not applied. The upper limit of the fifth-ranked group in the first year was announced as the threshold of the penalty 2 years later. If a hospital attained a quality score lower than this threshold 2 years later, the penalty would be applied. The incentive and the penalty were 1% of the cost paid by the National Health Insurance Corporation. In the second year, the 1% incentive was provided to the top performers and those that improved their quality of care. In the third year, the 1% penalty would have been applied to any hospitals that performed lower than the threshold.

Figure 2. Model of the Value Incentive Program in Korea.
However, each hospital scored higher than the threshold level so none were penalized. An incentive was given to all hospitals, some for being high performers and others for improving their quality of care.

VI. Amount of Incentives

The incentives awarded to the hospitals were Korean won (KRW) 857 million in total between 2008 and 2010. In the second year, KRW 453 million was provided to 21 hospitals, and in the third year KRW 404 million was awarded to 26 hospitals (Table 1). Because the overall quality scores improved, a penalty was not applied to any hospital.

QUALITY CHANGES BY THE VALUE INCENTIVE PROGRAM

I. Acute Myocardial Infarction

The results of the VIP and expanded VIP showed continuous and marked improvement in the CQSs of the AMI measures between 2007 and 2010. There was a 5.60-point increase in the mean CQS and 6.72 decrease in the standard deviation (or variation in performance) among institutions.

There were clear improvements in the process indicators, including the fibrinolytic administration rate within 60 minutes of hospital arrival and primary PCI rate within 120 minutes of hospital arrival. These results show that the margin for improvement was actually quite low because the hospitals already had high rates of aspirin administration at arrival, aspirin prescription at discharge, and beta-blocker prescription at discharge.

Table 1. Payment status of incentives and disincentives

| Year          | Set the disincentive threshold | Applied incentives | Applied incentives and disincentives |
|---------------|-------------------------------|--------------------|-------------------------------------|
| 1st year      | Total                         | AMI                | C-section                           |
|               |                               | 21                 | 15                                  |
|               |                               | 15                 | 17                                  |
| 2nd year      | Total                         | 45300              | 40400                               |
|               | AMI                           | 31000              | 25000                               |
|               | C-section                      | 14300              | 15400                               |
| 3rd year      | Total                         | -                  | None                                |
|               | AMI                           | -                  | -                                   |
|               | C-section                      | -                  | -                                   |

Unit: institution, 10,000 Korean won.
AMI, acute myocardial infarction; C-section, Caesarian section.

1 First grade and quality-improved institutions.
2 Number of overlapped institutions: nine institutions for the second year (first grade for both items: five institutions, first grade or quality-improved: four institutions); four institutions for the third year (first grade for both items: one institution, quality-improved in both items: one institution, first grade or quality-improved: two institutions).
3 Institutions under the disincentive threshold.

Figure 3. Improvement in composite quality scores of acute myocardial infarction care by year.
The CQSs of AMI care indicated improvement in all grades (Figure 3). The mean, minimum, and maximum values were improved and the standard deviation was reduced. In particular, quality improvement was more prominent in the lower grades.

II. Caesarian Section

The results of the VIP and expanded VIP showed continuous and marked improvement in standard scores of the C-section rate measured between 2007 and 2010. There was a 1.82-point decrease in the mean standard score and a 0.64-point decrease in the standard deviation among institutions.

Compared to 2009, the standard scores of the C-section rate in 2010 improved slightly, by 1.11 points. In 2010, general hospitals were included as eligible institutions for the VIP, and in this group, there was greater improvement (2.52 points) in the standard score. The C-section rate standard scores of general hospitals were lower than tertiary hospitals, suggesting that newer participants and lower-performing institutions showed greater improvement.

The results of the standard score of the C-section rate showed improvement in all grades (Figure 4). The mean, minimum, and maximum values improved and the standard deviation was reduced. In particular, quality improvement was more prominent in the lower grades.

With the demonstrated success of the VIP project, the Ministry of Health and Welfare expanded the program in 2011 to include general hospitals (data of 2010). However, general hospitals were excluded when their total number of delivery cases comes to less than 200 in C-section. Among the hospitals that treated AMI patients in 2010, 98% of tertiary hospitals (43) and 49% of general hospitals (71) were mandated to participate in the Expanded VIP. For the C-section Expanded VIP, all tertiary hospitals (44) and 46% of general hospitals (50) participated (data of 2010).

Five performance grades were sub-divided into nine grades. The amount of the incentive was also enlarged: 2% of the cost paid by NHIC would be provided to the highest performing group and 1% to the second-highest performing group (Figure 5). There were two thresholds of penalties. For the low performers whose quality scores were less than the upper limit of the lowest group, a 2% penalty would be applied. For those performing below the upper limit of the second-lowest group, a 1% penalty would be applied.

The expanded VIP also included a broader area of quality assessment. Acute stroke care and prophylactic use of antibiotics for surgical care were selected as the next items for inclusion in the VIP. Although mortality has steadily decreased, stroke is still the leading cause of death, and the geographical gap in the quality of stroke care is still a major concern.

Figure 4. Improvement in composite quality scores of Caesarean section rate by year.
care is significant. Furthermore, acute stroke increases the number of disabled persons, resulting in higher healthcare costs. Whereas HIRA and many providers are experienced in quality assessment and have achieved quality improvement in general, there are non-responding institutions with low performance despite the quality assessment incentive and public report. To address these challenges, the MOHW will include acute stroke care in the VIP in May 2013.

Excessive drug utilization is one of the challenges of Korea’s healthcare system. The irrelevant use of antibiotics leads to resistance to antibiotics and high surgical infection rates. The prophylactic use of antibiotics became a pay-for-performance subject in January 2012, and the target institutions are tertiary hospitals and general hospitals. The details of these issues, including the quality grades, are still under discussion.

**FURTHER CHALLENGES AND FUTURE DIRECTIONS**

The HIRA VIP was deemed applicable to the Korea healthcare system, but before it can be expanded further, the program must overcome several major concerns, outlined below.

**I. Inclusion of Resource Use Measure**

The results of the HIRA VIP revealed the lack of association between quality and low cost (Figure 6). To move toward meeting higher quality and efficiency, the HIRA prepared methods that adapted and applied resource use measures to the VIP in 2011. HIRA uses the costliness index (CI) and length of stay index (LI) as resource use measures. The CI and LI can be calculated after controlling the case-mix difference of each provider within the Korean diagnosis-related group (KDRG) as follows:

\[
CI = \frac{\text{observed medical cost}}{\text{expected medical cost}}, \quad LI = \frac{\text{observed length of stay}}{\text{expected length of stay}}.
\]

Utilizing the VIP, tertiary hospitals with a quality of care below that of general hospitals, or which have costs and/or lengths of stay above that of general hospitals, have been targeted for improvement.

**II. Rigorous Evaluation of Impact**

The impact of the VIP can be seen in that variation in quality has decreased and the mean quality has increased. However, this has not been rigorously evaluated, and needs further analysis for distinction from the time trend bias.

**III. Application of Value Incentive Program to the Changing Payment System**

In July 2012, the diagnosis related group (DRG) payment system was changed from voluntary participation to mandatory in seven DRG inpatient

Figure 5. Expanded Value Incentive Program model in Korea.
services as follows: Lens procedures, tonsillectomy and/or adenoidectomy, appendectomy, vaginal delivery, Caesarean section, inguinal and/or femoral hernia procedures, anal and/or perianal procedures, as authorized by the Health Insurance Policy Deliberation Committee in 2011. This expansion was established under the MOHW in accordance with the National Health Insurance Act and the DRG payment system. Because the VIP is a complementary payment system, the objective and incentive structure should be redesigned depending on the main payment system.

IV. Expansion of the Value Incentive Program to Primary Care Clinics

While increases in national medical expenses are mainly attributed to acute hospitals, higher-quality and more efficient payment systems are required without delay in primary care clinics and long-term care facilities. If the VIP is adopted in these areas, it should be redesigned to enhance the delivery system.

SUMMARY

Seven years after HIRA executed quality assessment (2000), the HIRA VIP was established (2007) for improving quality of care and decreasing the quality gaps. Thus far, the VIP has targeted AMI and C-section care. The results of the VIP showed continuous and marked improvement in the CQSs of the AMI and C-section measures between 2007 and 2010. Based on the VIP’s success, the HIRA VIP was expanded to include general hospitals. The HIRA VIP was deemed applicable to the Korean healthcare system, but before it can be expanded further, the program must address several major concerns.

CONFLICT OF INTEREST

The authors have no conflicts of interest with the material presented in this paper.

REFERENCES

1. Health Insurance Review and Assessment Service. Comprehensive quality report of National Health Insurance 2009. Seoul: Health Insurance Review and Assessment Service; 2010, p. 3-38, 60-68, 105-117 (Korean).
2. Health Insurance Review and Assessment Service. Comprehensive quality report of National Health Insurance 2010. Seoul: Health Insurance Review and Assessment Service; 2011, p. 3-43, 66-73, 127-141 (Korean).
3. Organisation for Economic Cooperation and Development. Health at a glance 2011: OECD indicators, OECD publishing. Paris: Organisation for Economic Co-operation and Development; 2011, p. 96-97.
4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial
infarction; A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44(3):E1-E211.

5. Spertus JA, Radford MJ, Every NR, Ellerbeck EF, Peterson ED, Krumholz HM, et al. Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: summary from the Acute Myocardial Infarction Working Group of the American Heart Association/ American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. Circulation 2003;107(12):1681-1691.

6. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361(9351):13-20.

7. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101(22):2557-2567.

8. Marciniak TA, Ellerbeck EF, Radford MJ, Kresowik TF, Gold JA, Krumholz HM, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998;279(17):1351-1357.

9. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316(7141):1337-1343.

10. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308(6921):81-106.

11. Park JS, Kang CH, Kim CY. Can cesarean section rate be used as a hospital-wide quality indicator in Korean hospitals? Korean J Obstet Gynecol 1997;40(9):1943-1953 (Korean).

12. Librero J, Peiro S, Calderon SM. Inter-hospital variations in caesarean sections. A risk adjusted comparison in the Valencia public hospitals. J Epidemiol Community Health 2000;54(8):631-636.

13. Joint Commission on Accreditation of Healthcare Organizations. Framework for improving performance: a guide for nurse. Oakbrook Terrace: Joint Commission on Accreditation of Healthcare Organizations; 1994, p. 205.

14. Mann LI, Gallant J. Modern indications for cesarean section. Am J Obstet Gynecol 1979;135(4):437-441.

15. Lee SI, Khang YH, Ha BM, Lee MS, Kang W, Koo HJ, et al. Inter-hospital comparison of cesarean section rates after risk adjustment. Korean J Prev Med 2001;34(4):337-346 (Korean).

16. Lee KS, Lee SI, Seo K, Do YM. Impact of risk adjustment with insurance claims data on cesarean delivery rates of healthcare organizations in Korea. J Prev Med Public Health 2005;38(2):132-140 (Korean).